(4Z)-6-iodo-4-{[(4-piperidin-1-ylmethyl)phenyl]amino}methyleneisoquinoline-1,3(2H,4H)-dione | 943347-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (4Z)-6-iodo-4-{[(4-piperidin-1-ylmethyl)phenyl]amino}methyleneisoquinoline-1,3(2H,4H)-dione
• 英文别名: (4Z)-6-iodo-4-[[4-(piperidin-1-ylmethyl)anilino]methylidene]isoquinoline-1,3-dione
• CAS: 943347-48-6
• 化学式: C₂₂H₂₂IN₃O₂
• 分子量: 487.34
• InChiKey: UHXGTSWGMUAMLW-MOSHPQCFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  28.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  61.44
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  4-(1-哌啶基甲基)苯胺 、 (4E)-6-iodo-4-(methoxymethylene)isoquinoline-1,3(2H,4H)-dione 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以48.3%的产率得到(4Z)-6-iodo-4-{[(4-piperidin-1-ylmethyl)phenyl]amino}methyleneisoquinoline-1,3(2H,4H)-dione
  参考文献：
  名称：

  4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as Potent and Selective Inhibitors of the Cyclin-Dependent Kinase 4 (CDK4)

  摘要：

  The cyclin-dependent kinases (CDKs), as complexes with their respective partners, the cyclins, are critical regulators of cell cycle progression. Because aberrant regulations of CDK4/cyclin D1 lead to uncontrolled cell proliferation, a hallmark of cancer, small-molecule inhibitors of CDK4/cyclin D1 are attractive as prospective antitumor agents. The series of 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-dione derivatives reported here represents a novel class of potent inhibitors that selectively inhibit CDK4 over CDK2 and CDK1 activities. In the headpiece of the 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)dione, a basic amine substitutent is required on the aniline ring for the CDK4 inhibitory activity. The inhibitory activity is further enhanced when an aryl or heteroaryl substituent is introduced at the C-6 position of the isoquinoline-1,3(2H,4H)-dione core. We present here SAR data and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.

  DOI：

  10.1021/jm800072z

文献信息

• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Wyeth LLC

  公开号：US07713994B2

  公开（公告）日：2010-05-11

  This invention provides compounds of Formula (I), having the structure where G1, G2, G3, G4, A1, A2, Y1, Y2, L1, Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了式（I）的化合物，其结构为G1，G2，G3，G4，A1，A2，Y1，Y2，L1，Z，e和f在此定义，或其药学上可接受的盐，用于治疗或预防癌症。
• SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS
  申请人：Wyeth

  公开号：EP1963273A2

  公开（公告）日：2008-09-03
• US7713994B2
  申请人：——

  公开号：US7713994B2

  公开（公告）日：2010-05-11
• [EN] SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND METHODS OF USE THEREOF<br/>[FR] ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES ET 1,4-DIHYDRO-3(2H)-ISOQUINOLONES ET PROCEDES D'UTILISATION CORRESPONDANT
  申请人：WYETH CORP

  公开号：WO2007075783A2

  公开（公告）日：2007-07-05

  [EN] This invention provides compounds of Formula (I), having the structure where G¹, G², G³, G⁴, A¹, A², Y¹, Y², L¹, Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.
  [FR] La présente invention concerne des composés de Formule (I) qui ont une structure où G¹, G², G³, G⁴, A¹, A², Y¹, Y², L¹, Z, e et f y sont définis, ou un sel pharmaceutiquement acceptable, qui sont utiles pour traiter un cancer ou l'empêcher.